Novel RXFP3 negative allosteric modulator RLX‐33 reduces alcohol self‐administration in rats.

There is much interest in identifying novel pharmacotherapeutic targets that improve clinical outcomes for the treatment of alcohol use disorder (AUD). One promising target for therapeutic intervention is the relaxin family peptide 3 (RXFP3) receptor, a cognate receptor for neuropeptide relaxin‐3, which has previously been implicated in regulating alcohol drinking behavior. Recently, we developed the first small‐molecule RXFP3‐selective negative allosteric modulator (NAM) RLX‐33. Therefore, the goal of the present work was to characterize the impact of this novel NAM on affective‐related behaviors and alcohol self‐administration in rats. First, the effects of RLX‐33 were tested on alcohol and sucrose self‐administration in Wistar and alcohol‐preferring P rats to determine the dose–response profile and specificity for alcohol. Then, we assessed the effects of systemic RLX‐33 injection in Wistar rats in a battery of behavioral assays (open‐field test, elevated zero maze, acoustic startle response test, and prepulse inhibition) and tested for alcohol clearance. We found that the lowest effective dose (5 mg/kg) reduced alcohol self‐administration in both male and female Wistar rats, while in alcohol‐preferring P rats, this effect was restricted to males, and there were no effects on sucrose self‐administration or general locomotor activity. The characterization of affective and metabolic effects in Wistar rats generally found few locomotor, affective, or alcohol clearance changes, particularly at the 5 mg/kg dose. Overall, these findings are promising and suggest that RXFP3 NAM has potential as a pharmacological target for treating AUD. [ABSTRACT FROM AUTHOR]